Indicated in Prasugrel and ticagrelor have been suggested as alternatives to clopidogrel for patients presenting with acute coronary syndrome
Recommendations on Switching Between Oral P2Y12 Inhibitors P2Y12 Inhibitor Patient Is Stopping P2Y12 Inhibitor to Be Started Recommendation Acute/Early Phase Clopidogrel Prasugrel 60 mg LD, irrespective of last clopidogrel dose; MD can be
Clopidogrel (Plavix) Prasugrel (Effient) Ticagrelor (Brilinta) Class: Thienopyridines: Thienopyridines: Cyclopentyltriazolopyrimidine: Dosing: Once daily: Once daily: Twice
Despite the evidence for the sustained efficacy and safety of prasugrel and ticagrelor with long-term treatment, many physicians limit treatment duration with these agents to the early weeks or months after the index
Plavix and Brilinta have different approved uses, but they’re both used to prevent cardiovascular events, such as heart attack or stroke, in people with acute coronary syndrome (ACS)
A